Soligenix, Inc. - Common Stock (SNGX)
2.9000
-0.3900 (-11.85%)
NASDAQ · Last Trade: Aug 9th, 2:53 PM EDT
Detailed Quote
| Previous Close | 3.290 |
|---|---|
| Open | 3.210 |
| Bid | 2.900 |
| Ask | 3.000 |
| Day's Range | 2.850 - 3.600 |
| 52 Week Range | 1.090 - 5.400 |
| Volume | 1,018,935 |
| Market Cap | 9.47M |
| PE Ratio (TTM) | -0.6760 |
| EPS (TTM) | -4.3 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 19,274,211 |
Chart
About Soligenix, Inc. - Common Stock (SNGX)
Soligenix Inc. is a biopharmaceutical company focused on developing innovative therapies for significant unmet medical needs. The company specializes in the research and clinical development of proprietary products aimed at treating rare diseases, as well as products intended for biodefense applications. With a strong emphasis on developing treatments for conditions such as oral mucositis and acute radiation syndrome, Soligenix takes a multi-faceted approach that includes leveraging its drug development platforms and engaging in collaborations with various stakeholders to advance its pipeline. The company’s dedication to improving patient outcomes drives its commitment to delivering safe and effective therapeutic options. Read More
News & Press Releases
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation
Soligenix (NASDAQ: SNGX) today announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators.” The article underscores the growing healthcare challenges of rare diseases among aging Americans and the urgent need for effective therapies. Soligenix is spotlighted for its HyBryte(TM) platform, a novel treatment for cutaneous T-cell lymphoma (CTCL), a rare skin cancer primarily affecting older adults. With U.S.-based manufacturing now established for HyBryte’s active ingredient, Soligenix demonstrates a commitment to domestic innovation and support for underserved patient populations.
Via Investor Brand Network · August 7, 2025
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
By Soligenix, Inc. · Via GlobeNewswire · August 7, 2025
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
NetworkNewsWire Editorial Coverage : As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments. The Trump administration’s “Make America Healthy Again” initiatives have highlighted this problem and focused on improving access to treatments and speeding up medical innovation. Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is working to advance this mission with its HyBryte(“TM”) platform, a new therapy for cutaneous T-cell lymphoma (“CTCL”), a rare form of skin cancer that largely impacts older adults. The company has successfully established U.S.-based manufacturing for HyBryte’s active ingredient, demonstrating the kind of domestic innovation that can significantly help this underserved patient group. Soligenix is one of several notable companies dedicated to making an impact in the pharmaceutical field, alongside Amgen Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and…
Via Investor Brand Network · August 6, 2025
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END
Via FinancialNewsMedia · August 6, 2025
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics
Soligenix (NASDAQ: SNGX) has been featured in a NetworkNewsWire editorial highlighting its progress in addressing rare diseases, particularly among aging populations. The piece emphasizes the urgent need for effective treatments as over 30 million Americans live with rare conditions, many lacking FDA-approved therapies. Soligenix’s HyBryte(TM) platform, targeting cutaneous T-cell lymphoma—a rare skin cancer affecting older adults—represents a promising solution. With successful domestic manufacturing of HyBryte’s active ingredient, the company advances its mission to serve this underserved demographic with innovative, U.S.-based therapies.
Via Investor Brand Network · August 5, 2025
Study Finds That Inflammation Markers in Diabetics Influence Depression Treatment Outcomes
On average, diabetics tend to suffer from depression at higher rates than is seen in the general population. A new study conducted by a team at the German Diabetes Center and other institutions in Germany has found that the markers of chronic inflammation influence how successful the treatments provided for depression will be for patients living with diabetes.
Via Investor Brand Network · August 5, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
By Soligenix, Inc. · Via GlobeNewswire · August 5, 2025
Unusual volume stocks are being observed in Monday's session.
Via Chartmill · August 4, 2025
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · August 4, 2025
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
NetworkNewsWire Editorial Coverage : As America’s population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration’s “Make America Healthy Again” initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is making strides with its HyBryte(“TM”) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (“CTCL”), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte’s active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and…
Via Investor Brand Network · August 4, 2025
Via FinancialNewsMedia · August 4, 2025
Loop Industries, Inc. (Nasdaq: LOOP) has launched Twist™, a branded, high-performance polyester resin made entirely from textile waste. Targeted at the fashion, sportswear, and home textile sectors, Twist™ delivers virgin-quality performance , full traceability, and up to 81% fewer CO₂ emissions than fossil-based alternatives.
Via AB Newswire · July 31, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Via Chartmill · July 31, 2025
Get a pulse on the US markets on Thursday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Via Chartmill · July 31, 2025
Via Benzinga · July 31, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via Chartmill · July 31, 2025
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s Disease
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing products for rare diseases, has completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in Behçet’s Disease, meeting the objective of demonstrating biological efficacy. In the open-label trial, SGX945 achieved a 40% improvement in the primary ulcer endpoint versus a historical placebo group from the apremilast (Otezla(R)) Phase 3 study, matching or exceeding apremilast outcomes despite treatment stopping at four weeks. Seven of eight patients reported reduced ulcer duration, number and pain, with benefits persisting through the follow-up period and no treatment-related adverse events reported. CEO Christopher J. Schaber said the results support advancing SGX945, including reformulation for home-based subcutaneous administration, as part of a broader strategy to address unmet needs in Behçet’s and other innate immune-related inflammatory conditions.
Via Investor Brand Network · July 31, 2025
Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast.
Via Benzinga · July 31, 2025
Via Benzinga · July 31, 2025
BioMedNewsBreaks — Targeting the Unmet: Soligenix Inc. (NASDAQ: SNGX) Building Portfolio for Rare Conditions
According to a recent article, “Behçet’s disease is rare, with prevalence estimates varying from 0.12 to 7.5 per 100,000 in the United States and Europe… Behçet’s disease is believed to be an autoimmune illness with both genetic and environmental components. Symptoms are most severe in young adulthood and generally ameliorate with age… Treatment involves medications designed to ease symptoms and prevent serious complications, such as blindness. Even with treatment, oral and genital flares can continue to occur for many patients and significantly affect quality of life and productivity. In addition, treatments can be associated with adverse effects, underscoring the need for more targeted and effective therapies.”
Via Investor Brand Network · July 25, 2025
Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel therapeutic aimed at alleviating this condition, with promising phase 3 data showing substantial improvements in the duration and severity of mucositis in head and neck cancer patients .
Via Investor Brand Network · July 24, 2025
Global Vaccination Goals at Risk as 14 Million Kids Miss Crucial Shots
Latest UN data indicates that at least 14 million kids didn’t receive life-saving shots of vaccines against tetanus, whooping cough and diphtheria in 2024. This threatens the attainment of global vaccination goals.
Via Investor Brand Network · July 24, 2025
Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial
Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and serves as principal investigator for the confirmatory phase 3 FLASH2 trial, which recent data from the IIS indicates is delivering promising treatment success in early-stage cutaneous T-cell lymphoma (“CTCL”).
Via Investor Brand Network · July 18, 2025